OrthoLogic unapproved bone stimulators cited in warning letter are custom devices, firm claims.
This article was originally published in The Gray Sheet
Executive SummaryORTHOLOGIC BONE STIMULATORS CITED IN WARNING LETTER ARE CUSTOM DEVICES and therefore do not require FDA approval via a premarket approval application supplement, the company has told FDA. In a May 31 warning letter, FDA charged that OrthoLogic "reconfigured" OrthoLogic 1000 bone stimulators for unapproved indications "without prior approval from the agency." OrthoLogic maintains that the products fit the definition of a custom device because they are manufactured in response to physician requests and are not generally available, kept in inventory or promoted for distribution. Custom devices are exempt from premarket approval requirements.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.